CGTX: Betting Against the Odds – Why Weak P-Values Won't Stop This Alzheimer's Story
When a company with FDA-aligned Phase 3 plans and a clean safety profile trades below the value of its NIH grants, something is mispriced.
Topic
Cognition Therapeutics
A collection of 4 issues
CGTX Part 1 : The Alzheimer's Gauntlet & Cognition's Second Big Chance
Cognition Therapeutics is attempting to succeed where giants have stumbled. After a dramatic clinical setback, a key discovery has given its lead drug a new, targeted path forward in the world's most challenging disease.
CGTX Part 2 : Beyond Alzheimer's - The Untapped Pipeline Potential
While Cognition Therapeutics' path in Alzheimer's has been redefined, the true long-term value of CT1812 may lie in its potential across a range of neurodegenerative diseases. From Dementia with Lewy Bodies to being a foundational therapy for all AD patients, the drug is far from a one-trick pony.
CGTX Part 3 : The Investor's Dilemma - Partnership, Dilution, or Bust?
With a clear regulatory path and a drug demonstrating broad potential, Cognition Therapeutics has the scientific assets. Now, it all comes down to the money. The company's future hinges on securing a strategic partnership, presenting investors with a classic high-risk, high-reward scenario.